Clin2
NCT05991986Possibly a fitNot yet recruiting

Retinal cell therapy for advanced age-related macular degeneration

Age-Related Macular Degeneration

Part of Eyes & vision clinical trials.

This trial tests if using your own stem cells to create retinal cells can help treat advanced age-related macular degeneration (AMD). If you have severe vision loss from AMD, this approach may restore some sight.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
10 people
Ages
55 years to 80 years
Study type
Observational

Who can take part

  • Age between 55 and 80 years
  • Diagnosed with advanced age-related macular degeneration
  • Vision in the study eye is worse than 20/200 (legally blind level)
  • No active cancer or history of cancer
  • No uncontrolled medical conditions like heart failure or liver disease
  • Not taking certain medications like immunosuppressants or blood thinners within the past 3 months

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06394232Recruiting· Phase 1/Phase 2
Testing a cell therapy for advanced dry AMD with geographic atrophy

This trial tests a new treatment called Eyecyte-RPE™, made from special cells that support the retina. It is given as a single injection under the retina during eye surgery. The study aims to see if it can help people with advanced dry age-related macular degeneration (AMD) who have large areas of damage (geographic atrophy) in the center of their vision.

Jālna, Maharashtra
NCT07594236Recruiting· Phase 1
Experimental Cell Therapy for Retinal Degeneration

This early-stage study tests a new cell-based treatment (C.001) for inherited retinal diseases that affect the back of the eye. The treatment may help slow vision loss or improve sight in people with geographic atrophy or Stargardt disease.

Beverly Hills, California
NCT04697095Recruiting
Testing immune cells from specific AMD eye types

This study collects immune cells (from a blood sample) from people with certain types of age-related macular degeneration (AMD) and compares how long they live. It may help researchers understand how immune-related changes relate to AMD outcomes.

Lyon
NCT06458595Recruiting· Phase 1/Phase 2
Gene therapy for wet age-related macular degeneration (nAMD)

This trial tests a gene therapy (KH658) as a one-time treatment for wet macular degeneration. It's for people whose condition has been stabilized with anti-VEGF injections, and aims to see if it is safe and can reduce the need for frequent eye injections.

Tianjin
NCT06662162Recruiting
Microcurrent therapy for dry age-related macular degeneration

This trial tests a new type of electrical stimulation, called microcurrent therapy, to see if it can help people with a certain form of age-related macular degeneration (AMD) that is not the "wet" kind. The treatment is delivered through an eye patch-like device and may slow vision loss or improve function.

Poway, California
NCT05445063Recruiting· Phase 1
iPSC eye-cell transplant for late dry macular degeneration

This Phase 1 study tests an experimental transplant made from your own cells to try to improve vision in people with advanced “late dry” age-related macular degeneration (AMD). It focuses first on safety, and may help some participants with limited central vision.

Beijing, Beijing Municipality

Hear when a new Age-Related Macular Degeneration trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.